Contrasting Agios Pharmaceuticals (NASDAQ:AGIO) & NutraLife Biosciences (OTCMKTS:NLBS)

Agios Pharmaceuticals (NASDAQ:AGIO) and NutraLife Biosciences (OTCMKTS:NLBS) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, analyst recommendations, valuation, risk and dividends.

Valuation & Earnings

This table compares Agios Pharmaceuticals and NutraLife Biosciences”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03 million	41.36	-$412.78 million	($7.25)	-5.18
NutraLife Biosciences	N/A	N/A	N/A	($0.02)	N/A

NutraLife Biosciences has lower revenue, but higher earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than NutraLife Biosciences, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Agios Pharmaceuticals and NutraLife Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
NutraLife Biosciences	N/A	N/A	N/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Agios Pharmaceuticals and NutraLife Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1	4	6	0	2.45
NutraLife Biosciences	0	0	0	0	0.00

Agios Pharmaceuticals presently has a consensus price target of $40.89, suggesting a potential upside of 8.80%. Given Agios Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Agios Pharmaceuticals is more favorable than NutraLife Biosciences.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

About NutraLife Biosciences

NutraLife BioSciences, Inc., together with its subsidiaries, engages in the development, manufacture, and distribution of nutraceutical, dietary, wellness, and cannabidiol (CBD) products. Its CBD products include cannabinoid-rich hemp oil derived from industrial hemp; tinctures; topical lotions and oils applied directly to the skin to treat pain or inflammation; face creams; massage oils; nutraceutical sprays with CBD as an added ingredient; and pet products. The company also offers other products, such as skincare and sanitizer products. NutraLife BioSciences, Inc. sells its products through nutralifebiosciences.com, as well as through private label distributors, online retailers, and retail outlets. The company was formerly known as NutraFuels, Inc. and changed its name to NutraLife BioSciences, Inc. in March 2019. NutraLife BioSciences, Inc. was incorporated in 2010 and is based in Coconut Creek, Florida.